Literature DB >> 8212668

Heparin-associated thrombocytopenia: no association of immune response with HLA.

A Greinacher1, G Mueller-Eckhardt.   

Abstract

Heparin-associated thrombocytopenia (HAT) is a severe adverse reaction of heparin therapy. Patients with the immunologic type of HAT are at risk of developing arterial and venous thromboembolic complications caused by an antibody which activates platelets in the presence of heparin. Yet, there are no means to identify patients at risk of developing HAT before heparin administration. We investigated the frequency of HLA class-I and class-II antigens in 47 patients with the immunologic type of HAT verified by a positive two-point heparin-induced platelet activation assay. Compared to a control group of 629 healthy individuals HLA antigens B8 and DR3 were less frequent, whereas DR4 and DR53 had a higher frequency. However, none of these antigens proved to be statistically significant. This is another example of an immunologically mediated disease showing no discernible association with the HLA system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212668     DOI: 10.1111/j.1423-0410.1993.tb02133.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  6 in total

1.  Association between the HLA-DRB1*03:01-DQB1*02:01 haplotype and PF4/heparin antibodies.

Authors:  Ray Zhang; Brian F Duffy; Vinzenz Lange; Charles S Eby; Chang Liu
Journal:  Blood Adv       Date:  2019-10-22

Review 2.  Heparin-induced thrombocytopenia: molecular pathogenesis.

Authors:  Seon Ho Lee; Chao Yan Liu; Gian PaoloVisentin
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant.

Authors:  Jiaqian Qi; Rui Zhang; Chengsen Cai; Hong Wang; Meng Zhou; Wenhong Shen; Yaqiong Tang; Tingting Pan; Depei Wu; Yue Han
Journal:  Ann Hematol       Date:  2021-04-12       Impact factor: 3.673

Review 4.  Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management.

Authors:  T E Warkentin
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

5.  Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.

Authors:  Tamam Bakchoul; Andreas Greinacher
Journal:  Ther Adv Hematol       Date:  2012-08

6.  Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia.

Authors:  Jason B Giles; Heidi E Steiner; Jerome Rollin; Christian M Shaffer; Yukihide Momozawa; Taisei Mushiroda; Chihiro Inai; Kathleen Selleng; Thomas Thiele; Claire Pouplard; Nancy M Heddle; Michiaki Kubo; Elise C Miller; Kiana L Martinez; Elizabeth J Phillips; Theodore E Warkentin; Yves Gruel; Andreas Greinacher; Dan M Roden; Jason H Karnes
Journal:  Blood Adv       Date:  2022-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.